




圖一、當歸萃取物、丹參萃取物、順鉑 及其聯用 60 hr 對肝癌細胞 HepG2 之抑制情形。Treatment 0：為不加入藥劑處理；Treatment 1：28.6 $\mu\text{g}\cdot\text{ml}^{-1}$ 當歸、2 $\mu\text{g}\cdot\text{ml}^{-1}$ 丹參及 0.2 $\mu\text{g}\cdot\text{ml}^{-1}$ 順鉑；Treatment 2：57.1 $\mu\text{g}\cdot\text{ml}^{-1}$ 當歸、5 $\mu\text{g}\cdot\text{ml}^{-1}$ 丹參及 0.5 $\mu\text{g}\cdot\text{ml}^{-1}$ 順鉑；Treatment 3：114 $\mu\text{g}\cdot\text{ml}^{-1}$ 當歸、10 $\mu\text{g}\cdot\text{ml}^{-1}$ 丹參及 1 $\mu\text{g}\cdot\text{ml}^{-1}$ 順鉑；Treatment 4：229 $\mu\text{g}\cdot\text{ml}^{-1}$ 當歸、20 $\mu\text{g}\cdot\text{ml}^{-1}$ 丹參及 2 $\mu\text{g}\cdot\text{ml}^{-1}$ 順鉑；Treatment 5：457 $\mu\text{g}\cdot\text{ml}^{-1}$ 當歸、40 $\mu\text{g}\cdot\text{ml}^{-1}$ 丹參及 5 $\mu\text{g}\cdot\text{ml}^{-1}$ 順鉑

Fig. 1. The effect of *Angelica* extract, *Salvia* extract, cisplatin and combination on HepG2 cells at 60 hrs. Treatment 0: without agent; Treatment 1: 28.6 $\mu\text{g}\cdot\text{ml}^{-1}$ *Angelica*, 2 $\mu\text{g}\cdot\text{ml}^{-1}$ *Salvia* and 0.2 $\mu\text{g}\cdot\text{ml}^{-1}$ cisplatin; Treatment 2: 57.1 $\mu\text{g}\cdot\text{ml}^{-1}$ *Angelica*, 5 $\mu\text{g}\cdot\text{ml}^{-1}$ *Salvia* and 0.5 $\mu\text{g}\cdot\text{ml}^{-1}$ cisplatin; Treatment 3: 114 $\mu\text{g}\cdot\text{ml}^{-1}$ *Angelica*, 10 $\mu\text{g}\cdot\text{ml}^{-1}$ *Salvia* and 1 $\mu\text{g}\cdot\text{ml}^{-1}$ cisplatin; Treatment 4: 229 $\mu\text{g}\cdot\text{ml}^{-1}$ *Angelica*, 20 $\mu\text{g}\cdot\text{ml}^{-1}$ *Salvia* and 2 $\mu\text{g}\cdot\text{ml}^{-1}$ cisplatin; Treatment 5: 457 $\mu\text{g}\cdot\text{ml}^{-1}$ *Angelica*, 40 $\mu\text{g}\cdot\text{ml}^{-1}$ *Salvia* and 5 $\mu\text{g}\cdot\text{ml}^{-1}$ cisplatin.